Deep tech requires deep analysis.

Biotech investing is different. So is Solt DB Invest. Members get access to our research, price targets, and a real-time margin of safety for emerging synthetic biology and biotech stocks. Not every biotech stock is a buy -- and it's okay to admit that.

Can biotech stocks beat the S&P 500?

We don't tell you every stock is a buy. But our research occasionally uncovers hidden gems. From our inception in May 2022 through April 2, 2024, stocks that earned our coveted Asymmetric Opportunity label delivered an average return of 26.2% and outperformed the S&P 500 by 6.7%.

Open-source databases (beta).

The Solt DB Biotech Company Database is a historical record of companies across all biotech sectors, not just biopharma. For investment research, biotech job searches, and tracking trends in the bioeconomy.